LMOD2

LMOD2 is a striated muscle-specific actin filament elongation factor that localizes to thin filament pointed ends and is essential for achieving mature thin filament length and normal contractile force in cardiac and slow skeletal muscle. In the heart, LMOD2 promotes actin assembly at pointed ends; its absence causes uniformly short thin filaments, severely reduced calcium-activated force production, blunted length-dependent activation, and dilated cardiomyopathy, with as little as ~20% of normal LMOD2 levels sufficient to maintain cardiac function (PMID:26487682, PMID:30102883). In slow skeletal muscle, LMOD2 specifically controls the length of the distal nebulin-free segment of thin filaments, whereas nebulin governs the proximal segment (PMID:33177085). Loss-of-function LMOD2 mutations cause neonatal dilated cardiomyopathy in humans, with extraordinarily short thin filaments and impaired force generation confirming its non-redundant role in human cardiac sarcomere assembly (PMID:31517052).

1. 2015 High

   Establishing that LMOD2 is required for thin filament elongation in the heart answered the fundamental question of what controls cardiac thin filament length at pointed ends, revealing that its loss causes short filaments, reduced force, and dilated cardiomyopathy — and that viral re-expression rescues the phenotype.

   Evidence Lmod2 global knockout mice analyzed by electron microscopy, micropillar force measurements, and AAV-mediated GFP-Lmod2 rescue

   PMID:26487682

   Open questions at the time

   • Mechanism by which LMOD2 nucleates or elongates actin at pointed ends not resolved at atomic level
   • Whether LMOD2 has additional functions beyond thin filament length regulation not addressed
   • Relative contributions of LMOD2 versus tropomodulin capping at pointed ends not dissected
2. 2018 High

   Conditional adult cardiac knockout demonstrated that LMOD2 is continuously required in the mature heart — not just during development — and established a quantitative dose–response relationship between LMOD2 protein levels, thin filament length, and contractile performance.

   Evidence Cardiac-specific conditional Lmod2 knockout in adult mice with isolated trabeculae force measurements and echocardiography

   PMID:30102883

   Open questions at the time

   • How LMOD2 turnover rate relates to thin filament homeostasis not quantified
   • Whether LMOD2 dose–response relationship holds in human myocardium not tested
3. 2019 High

   Identification of a human LMOD2 loss-of-function variant causing neonatal dilated cardiomyopathy with short thin filaments confirmed the gene's non-redundant role in human cardiac sarcomere assembly and established LMOD2 deficiency as a Mendelian cardiomyopathy.

   Evidence Exome sequencing of affected neonate, explanted heart thin filament length measurement, isolated cardiomyocyte force assays

   PMID:31517052

   Open questions at the time

   • Spectrum of pathogenic LMOD2 variants and genotype–phenotype correlations not established
   • Whether partial loss-of-function alleles produce milder phenotypes unknown
4. 2020 High

   Dissection of thin filament length control in skeletal muscle revealed that LMOD2 specifically governs the nebulin-free distal segment in slow fibers, resolving how pointed-end elongation and nebulin-based templating cooperate in a fiber-type-specific manner.

   Evidence Engineered nebulin super-repeat shortening/lengthening mouse models with structural and functional analysis compared with Lmod2 function

   PMID:33177085

   Open questions at the time

   • Molecular basis for fiber-type specificity of LMOD2 function not defined
   • Whether LMOD2 and nebulin physically interact at the transition zone not determined
5. 2021 Medium

   Identification of SNX17 as a binding partner that protects LMOD2 from lysosomal degradation provided the first insight into how LMOD2 protein stability is regulated, linking endosomal sorting to thin filament homeostasis.

   Evidence Co-immunoprecipitation of SNX17–LMOD2, SNX17 knockdown/knockout in neonatal rat ventricular myocytes and rats, lysosomal inhibitor rescue

   PMID:33936636

   Open questions at the time

   • SNX17–LMOD2 interaction identified by single-lab Co-IP without reciprocal validation or structural mapping
   • Whether other E3 ligases or degradation pathways also regulate LMOD2 turnover unknown
   • Physiological relevance of the SNX17–LMOD2 axis in human heart failure not demonstrated
6. 2025 Medium

   Demonstration that LMOD2 physically interacts with ACTC1 and that its loss alters muscle fiber type composition and myoblast proliferation extended LMOD2 function beyond thin filament elongation to include roles in myogenic differentiation and fiber-type specification.

   Evidence Co-IP of LMOD2–ACTC1, LMOD2 knockout in C2C12 cells with transcriptome analysis, lentivirus-mediated knockdown in vivo

   PMID:40745266

   Open questions at the time

   • LMOD2–ACTC1 interaction from single-lab Co-IP; stoichiometry and binding interface unresolved
   • Whether fiber-type changes are a direct consequence of LMOD2 loss or secondary to impaired thin filament function not distinguished
   • Transcriptional regulation of LMOD2 by MyoG validated only in C2C12 cells

• The atomic-level mechanism by which LMOD2 nucleates or elongates actin at pointed ends, the structural basis of its fiber-type-specific function, and how its protein turnover is coordinated with thin filament dynamics remain unresolved.
• No high-resolution structure of LMOD2 bound to actin pointed ends available
• Mechanism distinguishing LMOD2 from tropomodulin at pointed ends not molecularly defined
• In vivo dynamics of LMOD2 incorporation and turnover at the sarcomere not measured